| CAS: | 120638-55-3 |
| MF: | C15H11BrNNaO3 |
| MW: | 356.15 |
| EINECS: | 695-342-6 |
| Product Categories: | Inhibitors;Intermediates & Fine Chemicals;Pharmaceuticals;API |
| Mol File: | 120638-55-3.mol |
 |
|
| Bromfenac Sodium Chemical Properties |
| Melting point | 268-270°C (dec.) |
| storage temp. | Refrigerator |
| solubility | DMSO: ≥ 100 mg/mL (260.98 mM); Water: ≥ 100 mg/mL (260.98 mM) |
| Bromfenac Sodium Usage And Synthesis |
| Description | Duract was launched in the US as a potent, orally-active, long lasting peripheral analgesic with antiinflammatory properties. It is structurally similar to ketoprofen and diclofenac and can be prepared in three steps from 2-amino-4’-bromophenone using Gassman’s oxindole synthesis. Duract’s biological effects are a result of its ability to reduce prostaglandin production through inhibition of cyclooxygenase. As a 4-bromo derivative of Amfenac, this modification increased the duration of analgesic activity and antiinflammatory potency. It was also free of any CNS, cardiovascular or autonomic effects. In comparison, 5 mg of Duract was equipotent to 650 mg of ASA and 25 mg was slightly more potent than 400 mg of Ibuprofen. |
| Chemical Properties | Yellow Solid |
| Originator | American Home Products (US) |
| Uses | Bromfenac (Xibrom, ISTA Pharmaceuticals, Irvine, USA; Bronuck, Senju Pharmaceutical, Osaka, Japan) is indicated for the treatment of postoperative inflammation and the reduction of ocular pain in patients after undergoing cataract extraction. For this task, one drop of Xibrom may be applied to the affected eye twice daily beginning 24 hours after cataract surgery and continuing for the first 2 weeks of the postoperative period. The clinical safety and efficacy of bromfenac have been extensively studied in diverse comparative investigations, including the treatment of external or anterior ocular inflammatory diseases, allergic conjunctivitis, scleritis, and postoperative inflammation.The results of two phase III multicenter, randomized double-masked placebo-controlled clinical trials showed that bromfenac ophthalmic solution 0.09% was effective in the rapid resolution of ocular pain after cataract surgery, and there was a statistically significant difference between the bromfenac and placebo groups demonstrated in these phase III clinical trials. |
| Uses | Bromfenac is a non-steroidal anti-inflammatory agent. |
| Definition | ChEBI: The sesquihydrate of the sodium salt of bromfenac. It is used for the management of ocular pain and treatment of postoperative inflammation in patients who have undergone cataract extraction. |
| Brand name | Xibrom (Ista). |
Packing &shipping&Payment
Packing:25kg/drum
Shipping:by sea or by air
Payment:T/T,western union,moneygram
Packaging Details drum
Port:Tianjin
Lead Time :
| Quantity(Kilograms) | 1 - 10000 | >10000 |
| Est. Time(days) | 5 | To be negotiated |
Company information
Hebei Mojin Biotechnology Co., Ltd, Our company is a professional in 4'-Methylacetophenone,Levamisole hydrochloride ,N-Methylformamide and other chemical reagents research and development production enterprises. Our business covers more than 30 countries, most of the big customers come from Europe, America and other countries in the world, we can guarantee the quality and price. In recent decades, with the efforts of all employees, we have established many cooperative companies in shandong, henan, guangdong and other places. Our corporate purpose is based on the market, enhance the strength, take the road of scientific and environmental sustainable development, relying on the country. Technology r & d center, increase the investment in r & d, based on the domestic market, expand the international market, manufacturing quality products, sincere service to the society, into a modern, ecological, scientific and technological enterprise world.
Advantage
In stock
Japan
